Advertisement

Volume 130, Issue 3

Cover Figure: Role for hepcidin in innate immunity and infection prevention. See the article by Stefanova et al.

WASHINGTON, July 20, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non–transferrin-bound iron
This seminal paper brings direct proof for a major role of hepcidin in innate immunity, represents a great step forward in our understanding of the role of hepcidin in protection against certain infections, and provides tempting potential therapeutic applications for hepcidin analogues.

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma
Zinzani et al report that the immune checkpoint inhibitor pembrolizumab is active against the unique clinicopathologic entity of relapsed/refractory primary mediastinal large B-cell lymphoma. 

CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies
Al Sayed et al demonstrate a critical role for CD70 signaling in natural killer (NK) cell elimination of lymphoma, providing the preclinical groundwork for a new coactivating NK cell immunotherapy strategy.

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL
Erdmann et al examine the importance of phosphoinositide 3-kinase (PI3K) in diffuse large B-cell lymphoma (DLBCL) and rationalize dual inhibition of the p110α and p110δ isoforms.

Noninvasive detection of F8 int22h-related inversions and sequence variants in maternal plasma of hemophilia carriers
Hudecova and colleagues describe a simple, noninvasive assay for prenatal detection of hemophilia by droplet digital PCR on maternal peripheral blood.

Mouse RUNX1C regulates premegakaryocytic/erythroid output and maintains survival of megakaryocyte progenitors
RUNX1 is a key hematopoietic and endothelial transcription factor that plays critical roles in megakaryopoiesis and platelet formation. Draper et al demonstrate that 2 isoforms of the transcription factor RUNX1, which are generated by alternate promoter usage, play distinct functional roles during megakaryopoiesis.

An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease
Martin et al analyzed data from a prospective multicenter observational study and propose a new primary endpoint for clinical studies on chronic graft-versus-host disease that is associated with clinical benefit.

Can histologic transformation of follicular lymphoma be predicted and prevented?
Predicting the risk of histologic transformation in follicular lymphoma at diagnosis, monitoring patients, and evaluating prevention strategies are challenges of direct clinical relevance. This comprehensive review discusses the clinical, genetic, and biological factors that contribute to histologic transformation.

Eculizumab cessation in atypical hemolytic uremic syndrome
Merrill et al report in a well-defined series of adult patients with atypical hemolytic syndrome in remission after therapy with eculizumab, the monoclonal antibody directed against complement component C5, that treatment can be safely discontinued in most of the patients without subsequent recurrence.

 

This week's complete table of contents

Why Submit to Blood?

 


 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.